Laurent Greillier

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas, Arnaud Scherpereel, Anna K. Nowak et al. · The Lancet · 2021 · 1.1K citations · Full text

Checkmate 743, Medicine, Pathology +4

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 965 citations

Medicine, Pathology, Pleural Disease +5

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

R. Corre, Laurent Greillier, H. Le Caer et al. · Journal of Clinical Oncology · 2016 · 401 citations

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Daniel Morgensztern, Benjamin Besse, Laurent Greillier et al. · Clinical Cancer Research · 2019 · 309 citations · Full text

Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Anne‐Marie C. Dingemans, Lizza Hendriks, Thierry Berghmans et al. · Journal of Thoracic Oncology · 2019 · 281 citations · Full text